Solara Active Pharma Sciences Ltd

Solara Active Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Solara Active Pharma Sciences Ltd

₹ 512 -0.15%
01 Apr - close price
solara.co.in BSE: 541540 NSE: SOLARA
About

Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs.[1]

It was formed through demerger of API business from Strides Shasun Ltd (currently named as Stride Pharma Sciences). Subsequently, it also acquired the human API business from Sequent Scientific Ltd during the same time, making it a pure play API company.[2]

Key Points

Product Offerings
The company is a pure-play API manufacturer, offering a range of high-value commercial APIs and contract manufacturing services across 73+ countries. Its portfolio includes 60+ commercial APIs across key therapeutic segments, including anthelmintic, anti-malaria, anti-infective, etc. The top 10 molecules contribute to 84% of its total revenues. [1] [2] [3]

Website BSE NSE
  • Market Cap ₹ 2,147 Cr.
  • Current Price ₹ 512
  • High / Low ₹ 886 / 361
  • Stock P/E
  • Book Value ₹ 303
  • Dividend Yield 0.00 %
  • ROCE -8.65 %
  • ROE -33.4 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Debtor days have improved from 126 to 99.5 days.
  • Company's working capital requirements have reduced from 198 days to 124 days

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -1.45% over past five years.
  • Company has a low return on equity of -11.3% over last 3 years.
  • Promoters have pledged 40.7% of their holding.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE Healthcare BSE Allcap BSE SmallCap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
100.34 360.82 330.07 338.37 394.75 380.62 352.31 425.24 211.94 299.43 363.49 346.95 300.31
196.96 347.88 320.39 310.85 349.46 329.07 333.17 387.57 373.61 289.63 321.25 285.63 242.62
Operating Profit -96.62 12.94 9.68 27.52 45.29 51.55 19.14 37.67 -161.67 9.80 42.24 61.32 57.69
OPM % -96.29% 3.59% 2.93% 8.13% 11.47% 13.54% 5.43% 8.86% -76.28% 3.27% 11.62% 17.67% 19.21%
3.24 3.38 6.48 3.77 6.77 5.12 2.07 -2.32 -62.33 -121.69 1.38 0.32 1.49
Interest 17.82 21.46 22.50 21.96 23.64 21.96 25.51 24.47 25.37 30.62 30.87 28.28 26.54
Depreciation 28.37 27.74 28.05 28.56 27.89 26.40 25.83 26.14 25.96 25.10 25.07 25.34 24.54
Profit before tax -139.57 -32.88 -34.39 -19.23 0.53 8.31 -30.13 -15.26 -275.33 -167.61 -12.32 8.02 8.10
Tax % 0.00% -100.67% -44.23% -48.47% 20.75% 22.26% -34.02% 0.00% 0.00% 52.97% 0.00% 0.00% 0.00%
-139.57 0.22 -19.18 -9.91 0.42 6.46 -19.88 -15.26 -275.33 -256.40 -12.32 8.02 8.10
EPS in Rs -29.14 0.05 -4.00 -2.06 0.09 1.35 -4.14 -3.18 -57.36 -53.42 -3.42 2.23 2.25
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
521 1,387 1,322 1,617 1,268 1,444 1,289 1,310
462 1,173 1,065 1,232 1,187 1,309 1,384 1,139
Operating Profit 59 214 257 385 81 134 -95 171
OPM % 11% 15% 19% 24% 6% 9% -7% 13%
2 12 27 28 14 22 -184 -118
Interest 25 82 78 84 75 90 106 116
Depreciation 34 83 94 108 112 111 103 100
Profit before tax 2 61 112 221 -92 -45 -488 -164
Tax % 0% 3% 0% 0% -36% -50% 16%
2 59 112 221 -59 -22 -567 -253
EPS in Rs 17.06 31.42 46.13 -12.20 -4.63 -118.10 -52.36
Dividend Payout % 0% 22% 5% 11% 0% -49% 0%
Compounded Sales Growth
10 Years: %
5 Years: -1%
3 Years: -7%
TTM: -4%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 18%
Stock Price CAGR
10 Years: %
5 Years: 5%
3 Years: -7%
1 Year: 34%
Return on Equity
10 Years: %
5 Years: -2%
3 Years: -11%
Last Year: -33%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 25 26 27 36 36 36 36 40
Reserves 745 937 1,064 1,557 1,491 1,467 901 1,051
633 538 722 621 1,037 1,013 1,012 840
414 456 339 397 373 379 398 355
Total Liabilities 1,817 1,957 2,152 2,610 2,937 2,895 2,347 2,286
1,063 1,195 1,374 1,359 1,334 1,342 1,261 1,224
CWIP 70 39 40 88 239 238 256 272
Investments 19 18 18 18 15 16 14 2
666 705 719 1,145 1,350 1,298 815 788
Total Assets 1,817 1,957 2,152 2,610 2,937 2,895 2,347 2,286

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
50 166 242 154 -242 156 111
-85 -113 -359 -105 -243 -81 -5
67 -23 97 92 334 -113 -107
Net Cash Flow 32 30 -20 142 -151 -38 -0

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 185 76 63 109 141 136 99
Inventory Days 252 111 170 149 321 258 163
Days Payable 420 126 131 154 150 139 140
Cash Conversion Cycle 17 62 102 104 312 256 123
Working Capital Days 112 36 68 119 253 216 124
ROCE % 10% 12% 15% -1% 2% -9%

Shareholding Pattern

Numbers in percentages

9 Recently
Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
39.71% 40.40% 40.41% 40.41% 40.98% 39.31% 37.19% 30.49% 30.49% 37.27% 37.27% 37.23%
19.42% 17.93% 18.47% 19.26% 19.30% 18.71% 17.86% 16.62% 15.80% 14.00% 14.25% 14.67%
3.64% 3.10% 2.97% 3.01% 2.75% 1.75% 1.79% 1.75% 2.97% 2.83% 3.37% 3.19%
37.22% 38.57% 38.16% 37.32% 36.95% 40.22% 43.16% 51.14% 50.73% 45.89% 45.11% 44.92%
No. of Shareholders 77,22882,71083,31979,14976,32575,41774,47372,91873,91277,17071,88283,148

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls